CoreValve, S.A.'s 18-French Revalving(RM) System Demonstrated 'Live' At TCT 2006

IRVINE, Calif.--(BUSINESS WIRE)--CoreValve ( announced today that its third-generation, proprietary aortic heart valve was implanted successfully — non-surgically — in a ‘high-risk’ patient using CoreValve’s percutaneous, 18-French ReValving™ System, at the 18th annual ‘Transcatheter Cardiovascular Therapeutics’ (TCT) scientific symposium sponsored by the Cardiovascular Research Foundation (CRF). TCT is one of the largest interventional vascular medicine meetings in the world.

Back to news